These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11227673)

  • 1. Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B.
    Kiyosawa K; Tanaka E
    J Gastroenterol; 2001 Feb; 36(2):139-41. PubMed ID: 11227673
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant.
    Someya T; Suzuki Y; Arase Y; Kobayashi M; Suzuki F; Tsubota A; Saitoh S; Chayama K; Murashima N; Ikeda K; Kumada H
    J Gastroenterol; 2001 Feb; 36(2):133-6. PubMed ID: 11227671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
    Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
    Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
    Gervain J; Papp I; Csöndes M; Nemesánszky E; Rácz I; Ribiczey P; Telegdy L; Tornai I; Weisz G
    Orv Hetil; 2003 Jun; 144(25):1251-6. PubMed ID: 12901182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High-flux detection of HBV lamivudine resistant strains by genechip and analysis of mutant hotspots in those strains].
    Li B; Zhou BP; Peng JF; Chen LY; Li LX; Wang ZQ; Wang M; Liu SY; Jiang XL
    Zhonghua Gan Zang Bing Za Zhi; 2004 Nov; 12(11):673-6. PubMed ID: 15623377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U; Ural O; Findik D
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
    Mori K; Minami M; Kirishima T; Kunimoto K; Okita M; Nakayama M; Makiyama A; Yamaoka J; Nakajima T; Yasui K; Itoh Y; Okanoue T
    Intervirology; 2006; 49(5):274-80. PubMed ID: 16714856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lamivudine therapy for Japanese patients with cirrhosis B.
    Okanoue T; Mori K; Kirishima T; Kunimoto K; Yasui K; Itoh Y; Minami M
    Intervirology; 2003; 46(6):394-9. PubMed ID: 14688458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analyzing clinical character of patients resistant to lamivudine with chronic hepatitis B with YMDD mutations or non-YMDD mutations].
    Yang DH; Xie YJ; Liang WF; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):496-7. PubMed ID: 15329216
    [No Abstract]   [Full Text] [Related]  

  • 14. [Detection of lamivudine-resistant hepatitis B virus].
    Matsumura M
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():175-9. PubMed ID: 15453310
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with lamivudine against hepatitis B virus.
    Jaeckel E; Manns MP
    Intervirology; 1997; 40(5-6):322-36. PubMed ID: 9675637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy.
    Pai SB; Bozdayi AM; Pai RB; Beker T; Sarioglu M; Turkyilmaz AR; Grier J; Yurdaydin C; Schinazi RF
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2618-24. PubMed ID: 15980328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.
    Akman SA; Kose S; Halicioglu O
    Int J Infect Dis; 2010 Mar; 14(3):e236-9. PubMed ID: 19665408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
    Amini-Bavil-Olyaee S; Hosseini SY; Sabahi F; Alavian SM
    Int J Infect Dis; 2008 Jan; 12(1):83-7. PubMed ID: 17698384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.